United States: Wilmerhale Reps Emergent Biosolutions In $96M Acquisition Of Glaxosmithkline Anthrax Drug
Last Updated: August 9 2017

Emergent BioSolutions, which offers specialized products to healthcare providers and governments to address medical needs and emerging health threats, announced it would acquire a drug for treating inhaled anthrax from pharmaceutical giant GlaxoSmithKline in an all-cash deal worth up to $96 million. The deal is expected to close by the end of the year.

The WilmerHale team representing Emergent BioSolutions was led by Jeffrey Hermanson and includes Belinda Juran, Sam Rothberg, Alex Civetta, Jasmine Haddad, Hartmut Schneider, Julie Hogan Rodgers and Bruce Manheim.

To learn more about the acquisition, read Emergent BioSolutions' press release.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By David Gammell
By Jonathan Cedarbaum, D. Reed Freeman, Jr., Alan Schoenfeld, Heather Zachary, Stephanie Simon
By Alan Wilson, Jonathan Wolfman
By Ambassador Charlene Barshefsky, Naboth van den Broek, David Ross, Patrick J. McLain, David Horn
By Frederick Saugman
By Bill Warren
By Michael Connor, H. David Gold, Sarah Judkins, Andrew L. Spielman
By Lester Ross, Tingting Liu
By H. David Gold, Rachel Jacobson, Heidi K. Ruckriegle
By Joseph Mueller, Thomas Saunders, Leslie Pearlson
Font Size: